Inhibikase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share

Net Loss Per Share

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Net Loss Per Share

13.

Net Loss Per Share

The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders:


	Nine Months Ended September 30,
	2022			2021
Numerator:
Net loss	$	(13,775,103	)	$	(9,744,444	)
Denominator:
Weighted-average number of common shares outstanding – basic and diluted		25,219,931			15,868,421
Net loss per share applicable to common stockholders – basic and diluted	$	(0.55	)	$	(0.61	)

The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented:


	Nine Months Ended September 30,
	2022		2021
Options to purchase shares of stock		4,028,078		3,630,044
Warrants to purchase shares of stock		1,561,913		1,561,913
Total		5,589,991		5,191,957